Baidu
map

JAMA Psychiatry:氯氮平一线治疗抗药性精神分裂症

2019-10-15 MedSci MedSci原创

氯氮平是抗药性精神分裂症患者的首先治疗手段

近日研究人员开展系统综述及荟萃分析研究,比较了氯氮平与非氯氮平二代抗精神病药物(NC-SGAs)治疗抗药性精神分裂症患者的疗效。

研究收集截至2018年12月17日的相关研究,研究的主要终点为住院及全因停药,次要终点包括疗效及安全性研究。

63个研究队列,包含109341名患者,其中男性占60.3%,平均年龄38.8岁,病程11.0年,随访时间19.1个月。相比于NC-SGAs,氯氮平显著降低患者住院(RR=0.817)及全因停药(RR=0.732)风险。氯氮平在改善患者整体症状(SMD=-0.302)以及临床整体严重程度评估(SMD=-1.182)方面更具优势,并且可增加患者体重、BMI并降低糖尿病风险。

研究认为,氯氮平是抗药性精神分裂症患者的首先治疗手段。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1792154, encodeId=04941e921541e, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Wed Jul 15 08:12:00 CST 2020, time=2020-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404119, encodeId=be021404119c2, content=<a href='/topic/show?id=7366e6493be' target=_blank style='color:#2F92EE;'>#精神分裂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76493, encryptionId=7366e6493be, topicName=精神分裂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Oct 17 09:12:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438439, encodeId=f37e1438439df, content=<a href='/topic/show?id=d2f164102fe' target=_blank style='color:#2F92EE;'>#氯氮平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64102, encryptionId=d2f164102fe, topicName=氯氮平)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Oct 17 09:12:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495389, encodeId=ebbf149538960, content=<a href='/topic/show?id=cdd8556826f' target=_blank style='color:#2F92EE;'>#抗药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55682, encryptionId=cdd8556826f, topicName=抗药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=110a9169530, createdName=songbq, createdTime=Thu Oct 17 09:12:00 CST 2019, time=2019-10-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1792154, encodeId=04941e921541e, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Wed Jul 15 08:12:00 CST 2020, time=2020-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404119, encodeId=be021404119c2, content=<a href='/topic/show?id=7366e6493be' target=_blank style='color:#2F92EE;'>#精神分裂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76493, encryptionId=7366e6493be, topicName=精神分裂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Oct 17 09:12:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438439, encodeId=f37e1438439df, content=<a href='/topic/show?id=d2f164102fe' target=_blank style='color:#2F92EE;'>#氯氮平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64102, encryptionId=d2f164102fe, topicName=氯氮平)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Oct 17 09:12:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495389, encodeId=ebbf149538960, content=<a href='/topic/show?id=cdd8556826f' target=_blank style='color:#2F92EE;'>#抗药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55682, encryptionId=cdd8556826f, topicName=抗药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=110a9169530, createdName=songbq, createdTime=Thu Oct 17 09:12:00 CST 2019, time=2019-10-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1792154, encodeId=04941e921541e, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Wed Jul 15 08:12:00 CST 2020, time=2020-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404119, encodeId=be021404119c2, content=<a href='/topic/show?id=7366e6493be' target=_blank style='color:#2F92EE;'>#精神分裂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76493, encryptionId=7366e6493be, topicName=精神分裂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Oct 17 09:12:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438439, encodeId=f37e1438439df, content=<a href='/topic/show?id=d2f164102fe' target=_blank style='color:#2F92EE;'>#氯氮平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64102, encryptionId=d2f164102fe, topicName=氯氮平)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Oct 17 09:12:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495389, encodeId=ebbf149538960, content=<a href='/topic/show?id=cdd8556826f' target=_blank style='color:#2F92EE;'>#抗药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55682, encryptionId=cdd8556826f, topicName=抗药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=110a9169530, createdName=songbq, createdTime=Thu Oct 17 09:12:00 CST 2019, time=2019-10-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1792154, encodeId=04941e921541e, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Wed Jul 15 08:12:00 CST 2020, time=2020-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404119, encodeId=be021404119c2, content=<a href='/topic/show?id=7366e6493be' target=_blank style='color:#2F92EE;'>#精神分裂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76493, encryptionId=7366e6493be, topicName=精神分裂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Oct 17 09:12:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438439, encodeId=f37e1438439df, content=<a href='/topic/show?id=d2f164102fe' target=_blank style='color:#2F92EE;'>#氯氮平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64102, encryptionId=d2f164102fe, topicName=氯氮平)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Oct 17 09:12:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495389, encodeId=ebbf149538960, content=<a href='/topic/show?id=cdd8556826f' target=_blank style='color:#2F92EE;'>#抗药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55682, encryptionId=cdd8556826f, topicName=抗药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=110a9169530, createdName=songbq, createdTime=Thu Oct 17 09:12:00 CST 2019, time=2019-10-17, status=1, ipAttribution=)]
    2019-10-17 songbq

相关资讯

Alkermes的精神分裂症候选药物ALKS 3831将扩大向FDA的营销申请,以用于治疗I型双相情感障碍

Alkermes周一表示,在与FDA会面后,该制药商计划扩大其ALKS 3831在美国的营销申请,将ALKS 3831与非典型抗精神病药奥氮平和阿片类拮抗剂samidorphan联合治疗I型双相情感障碍和精神分裂症,是一种每日一次的口服药物。Alkermes预计将在第四季度提交申请文件,将包括ALKS 3831治疗精神分裂症患者的ENLIGHTEN临床结果,以及比较ALKS 3831和Eli Li

Cell :精神分裂症中诡异的小清蛋白神经元

精神分裂症的易感性由遗传因素和大脑发育和成熟过程中应激和感染等不良事件决定的。然而,这种慢性精神疾病具有一个显着特征是疾病的关键诱发过程可以出现在幼儿期甚至胚胎期,但精神病症状首先出现在青春期后期和青年期之间的过渡期。已经有证据表明精神分裂症与前额叶皮层和海马中小清蛋白阳性(PV+)神经元异常有关,但是具体机制未明。

治疗精神分裂症:SEP-363856已获FDA突破性疗法认定

Sunovion和PsychoGenics公司近日宣布,美国食品和药品监督管理局(FDA)已经授予SEP-363856突破性疗法认定以治疗精神分裂症。突

Lancet:32种常见抗精神分裂药物的疗效及不良事件差异研究

32种常见口服抗精神病药物之间有一定的疗效差异,副作用的差异更为明显

首发精神分裂症的治疗:联用西酞普兰

首发精神分裂症(first-episode schizophrenia,FES)患者经常会表现出阴性症状、亚综合症抑郁和功能障碍,以往有证据表明抗抑郁药可以减轻慢性精神分裂症患者的阴性症状,但并不推荐用于不伴有抑郁的 FES 患者的维持治疗。由于此前并没有研究调查抗抑郁药对于 FES 患者的精神病理学相关作用,纽约 Nathan Kline 精神病研究所的 Goff 等研究者大胆假设:西酞普兰对

Nature Genetics:双相情感障碍的全基因组关联分析

双相情感障碍是一种高度遗传的精神疾病。Eli A. Stahl等人通过对欧洲人群的20 352位患者和31 358位对照进行全基因组关联分析(GWAS),并在额外的9412例患者和137760位对照中对筛查出的822个发生率低于1X10-4的突变进行分析。GWAS在全基因组中发现的19个具有显著性(P<5×108)的变异中有8个在全基因组联合分析中不显著,这与效应大小和有限的功率一致,但也具

Baidu
map
Baidu
map
Baidu
map